Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New European Vaccine Initiative

Published: Tuesday, November 26, 2013
Last Updated: Tuesday, November 26, 2013
Bookmark and Share
Leading organisations have joined forces to rapidly assess and communicate the benefits and risks of vaccines.

ADVANCE, as the project is called, is in collaboration between European researchers, public health, regulatory agencies and vaccine manufacturers. Karolinska Institutet coordinates the Swedish participation in the project.

The initiative aims to help government agencies and decision-makers in the healthcare field to make quick and well-informed decisions regarding strategies for vaccinating the European population. Such a framework would make it easier for regulators and public health authorities to make fast, more informed decisions regarding vaccination strategies, and help to maintain public confidence in immunisation, particularly when questions are raised about the safety of specific vaccines.

Researchers at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet will participate in the scientific studies that are planned within the ADVANCE project and also contribute their expertise regarding the establishment of the framework. Other Swedish participants include the Swedish Institute for Communicable Disease Control (SMI) and the European Centre for Disease Prevention and Control (ECDC), which has its headquarters in Sweden. Other important partners include the European equivalent of the Swedish Medical Products Agency, EMA, Erasmus University Rotterdam, and several major pharmaceutical companies.

The initiative is funded by the Innovative Medicines Initiative (IMI), which in turn is a collaboration between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). ADVANCE (Accelerated Development of Vaccine Benefit-risk Collaboration in Europe) receives the equivalent of SEK 95 million in funding over five years. Karolinska Institutet will receive SEK 1.4 million over the same period.

"This collaboration is unique as it is the first time that a European framework is created for evaluating vaccines. It is important that we participate in this project as Sweden has excellent prerequisites, through our health care data register, for evaluating vaccines on a population-based level", says Lisen Arnheim Dahlström, project investigator from Karolinska Institutet.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Possible Goal for New Tuberculosis-Vaccine Identified
A new study shows for the first time the essential role of the molecule SOCS3 in the control of Tuberculosis.
Monday, July 08, 2013
New Hope for Setback-dogged Cancer Treatment
Researchers at Karolinska Institutet announce breakthrough in the study of how IGF-1 receptor-binding antibodies can help those with cancer.
Wednesday, November 28, 2012
Possible New Therapy for the Treatment of a Common Blood Cancer
Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma.
Friday, September 07, 2012
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!